Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Veru ( (VERU) ) has provided an update.
On October 30, 2025, Veru Inc. entered into an underwriting agreement with Canaccord Genuity LLC for a public offering of 8,400,000 shares of its common stock, along with Series A and B warrants, expected to raise approximately $23.4 million. The proceeds will primarily fund the development of enobosarm, focusing on the Phase 2b PLATEAU clinical study, and for general corporate purposes. The offering is expected to close on or about October 31, 2025, subject to customary conditions, and aims to strategically position Veru in the biopharmaceutical market by advancing its clinical pipeline.
The most recent analyst rating on (VERU) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Veru stock, see the VERU Stock Forecast page.
Spark’s Take on VERU Stock
According to Spark, TipRanks’ AI Analyst, VERU is a Neutral.
Veru’s overall stock score is primarily impacted by its weak financial performance and valuation concerns. While technical analysis provides some neutral signals, the company’s ongoing financial losses and cash flow issues overshadow potential clinical advancements.
To see Spark’s full report on VERU stock, click here.
More about Veru
Veru Inc. is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases.
Average Trading Volume: 166,321
Technical Sentiment Signal: Sell
Current Market Cap: $51.3M
Learn more about VERU stock on TipRanks’ Stock Analysis page.